The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Michinori Ogura
Research Funding - Sympio Pharmaceuticals
Kiyoshi Ando
No relevant relationships to disclose
Nozomi Niitsu
No relevant relationships to disclose
Seok Jin Kim
No relevant relationships to disclose
Ken Ohmachi
No relevant relationships to disclose
Naoki Takahashi
No relevant relationships to disclose
Toshiki Uchida
No relevant relationships to disclose
Naoto Takahashi
No relevant relationships to disclose
Naokuni Uike
No relevant relationships to disclose
Hyeon Seok Eom
No relevant relationships to disclose
Yee Soo Chae
No relevant relationships to disclose
Takashi Terauchi
No relevant relationships to disclose
Ukihide Tateishi
No relevant relationships to disclose
Mitsuaki Tatsumi
No relevant relationships to disclose
Won Seog Kim
Consultant or Advisory Role - Celltrion; Millennium
Research Funding - Sympio Pharmaceuticals
Cheolwon Suh
Research Funding - SymBio Pharmaceuticals
Kensei Tobinai
Consultant or Advisory Role - SymBio Pharmaceuticals
Research Funding - SymBio Pharmaceuticals